Chronic inflammatory disorders and reproduction;Rhumatisme inflammatoire chronique et procréation

Gynecologie Obstetrique et Fertilite

Volumn 35, Issue 9, 2007, Pages 848-852

  Fautrel, B ^a   Benhamou, M ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Connective tissue diseases; Fertility; Inflammatory disorders; Pregnancy; Rheumatic diseases; Teratogenicity

Indexed keywords

ANTIMALARIAL AGENT; ANTIRHEUMATIC AGENT; AZATHIOPRINE; CYCLOOXYGENASE 2 INHIBITOR; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; GLUCOCORTICOID; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ARTICLE; DISEASE ACTIVITY; FERTILITY; FETUS DEVELOPMENT; HUMAN; PATIENT ASSESSMENT; PREGNANCY DISORDER; PREGNANCY OUTCOME; PREGNANT WOMAN; RHEUMATIC FEVER; RHEUMATOID ARTHRITIS; RISK FACTOR; TERATOGENESIS; ANTIPHOSPHOLIPID SYNDROME; CLASSIFICATION; FEMALE; INFLAMMATION; PREGNANCY; PREGNANCY COMPLICATION; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANTIPHOSPHOLIPID SYNDROME; ARTHRITIS, RHEUMATOID; FEMALE; FETAL DEVELOPMENT; HUMANS; INFLAMMATION; LUPUS ERYTHEMATOSUS, SYSTEMIC; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME;

EID: 34548660204     PISSN: 12979589     EISSN: 17696682     Source Type: Journal    
DOI: 10.1016/j.gyobfe.2007.07.013     Document Type: Article

References (24)

1. Gordon C. Pregnancy and autoimmune diseases. Best Pract. Res. Clin. Rheumatol. 18 3 (2004) 359-379
2. Lockshin M.D. Treating rheumatic diseases in pregnancy: dos and don'ts. Ann. Rheum. Dis. 65 Suppl 3 (2006) iii58-iii60
3. Ostensen M. New insights into sexual functioning and fertility in rheumatic diseases. Best Pract. Res. Clin. Rheumatol. 18 2 (2004) 219-232
4. Cutolo M., Capellino S., Sulli A., Serioli B., Secchi M.E., Villaggio B., et al. Estrogens and autoimmune diseases. Ann. N. Y. Acad. Sci. 1089 (2006) 538-547
5. Meyer O. Making pregnancy safer for patients with lupus. Joint Bone Spine 71 3 (2004) 178-182
6. Canadian Study Group. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group. N. Engl. J. Med. 324 3 (1991) 150-154
7. Costedoat-Chalumeau N., Amoura Z., Huong D.L., Lechat P., and Piette J.C. Safety of hydroxychloroquine in pregnant patients with connective tissue diseases. Review of the literature. Autoimmun. Rev. 4 2 (2005) 111-115
8. Chakravarty E.F., Sanchez-Yamamoto D., and Bush T.M. The use of disease modifying antirheumatic drugs in women with rheumatoid arthritis of childbearing age: a survey of practice patterns and pregnancy outcomes. J. Rheumatol. 30 2 (2003) 241-246
9. Lockshin M.D. Sex differences in autoimmune disease. Orthop. Clin. North Am. 37 4 (2006) 629-633
10. De Man Y.A., Hazes J.M., Van de Geijn F.E., Krommenhoek C., and Dolhain R.J. Measuring disease activity and functionality during pregnancy in patients with rheumatoid arthritis. Arthritis Rheum. 57 5 (2007) 716-722
11. Skomsvoll J.F., Ostensen M., Baste V., and Irgens L.M. Number of births, interpregnancy interval, and subsequent pregnancy rate after a diagnosis of inflammatory rheumatic disease in Norwegian women. J. Rheumatol. 28 10 (2001) 2310-2314
12. Skomsvoll J.F., Ostensen M., and Schei B. Reproduction in women reporting chronic musculoskeletal disorders. Scand. J. Rheumatol. 29 2 (2000) 103-107
13. Temprano K.K., Bandlamudi R., and Moore T.L. Antirheumatic drugs in pregnancy and lactation. Semin. Arthritis Rheum. 35 2 (2005) 112-121
14. Skopouli F.N., Papanikolaou S., Malamou-Mitsi V., Papanikolaou N., and Moutsopoulos H.M. Obstetric and gynaecological profile in patients with primary Sjogren's syndrome. Ann. Rheum. Dis. 53 9 (1994) 569-573
15. Steen V.D., and Medsger Jr. T.A. Fertility and pregnancy outcome in women with systemic sclerosis. Arthritis Rheum. 42 4 (1999) 763-768
16. Blake D.J., Maisiak R., Alarcon G.S., Holley H.L., and Brown S. Sexual quality-of-life of patients with arthritis compared to arthritis-free controls. J. Rheumatol. 14 3 (1987) 570-576
17. Elst P., Sybesma T., Van der Stadt R.J., Prins A.P., Muller W.H., and den Butter A. Sexual problems in rheumatoid arthritis and ankylosing spondylitis. Arthritis Rheum. 27 2 (1984) 217-220
18. Bhadauria S., Moser D.K., Clements P.J., Singh R.R., Lachenbruch P.A., Pitkin R.M., et al. Genital tract abnormalities and female sexual function impairment in systemic sclerosis. Am. J. Obstet. Gynecol. 172 2 Pt 1 (1995) 580-587
19. Gordon D., Beastall G.H., Thomson J.A., and Sturrock R.D. Androgenic status and sexual function in males with rheumatoid arthritis and ankylosing spondylitis. Q. J. Med. 60 231 (1986) 671-679
20. Ghazeeri G.S., and Kutteh W.H. Autoimmune factors in reproductive failure. Curr. Opin. Obstet. Gynecol. 13 3 (2001) 287-291
21. Boumpas D.T., Austin III H.A., Vaughan E.M., Yarboro C.H., Klippel J.H., and Balow J.E. Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann. Intern. Med. 119 5 (1993) 366-369
22. Kumar R., Biggart J.D., McEvoy J., and McGeown M.G. Cyclophosphamide and reproductive function. Lancet 1 7762 (1972) 1212-1214
23. Slater C.A., Liang M.H., McCune J.W., Christman G.M., and Laufer M.R. Preserving ovarian function in patients receiving cyclophosphamide. Lupus 8 1 (1999) 3-10
24. Mok C.C., Lau C.S., and Wong R.W. Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy. Arthritis Rheum. 41 5 (1998) 831-837